Abstract C007: Racial differences in feasibility and perceived value of electronic symptom monitoring in a cohort of Black and White bladder and prostate cancer patients

Prostate cancer is a significant impediment that can reduce physical functional status. Mobility is fundamental for quality of life and church attendance to be associated with improved physical functioning. Few studies have examined how religious participation have implications for mobility limitation among men in general and among prostate cancer survivors in particular. The purpose of this study was to assess the association between church attendance and mobility limitation among Black and White prostate cancer patients and survivors. Data for this investigation were drawn from the Diagnosis and Decisions in Prostate Cancer Treatment Outcomes Study that consisted of 804 Black and White men with complete information on the primary outcome and predictor variables. Mobility limitation was the primary outcome variable, and church attendance was the main independent variable. The analytic sample was almost equally divided between Black ( N = 382) and White men ( N = 422). The proportion of Black men reporting mobility limitation (30.09%) more than doubled the corresponding percentage for White men (14.7%). Black men had a higher proportion of individuals who reported weekly church attendance (49.2% vs. 45.0%). Fully adjusted modified Poisson regression models produced results indicating that respondents attending church weekly had a lower mobility limitation prevalence (PR = 0.56, 95% CI [0.39, 0.81]) than those never attending church. Results from this study contribute to the body of evidence asserting the health benefits of church attendance. These findings suggest that health providers should consider how religion and spirituality can present opportunities for improved outcomes in prostate cancer patients and survivors.

Download Full-text

Abstract B33: Genome-wide methylation analyses reveal racial differences in blood DNA of prostate cancer patients from the North Carolina-Louisiana Prostate Cancer Project (PCaP) cohort.

10.1158/1055-9965.disp12-b33 ◽

2012 ◽

Author(s):

Anna Woloszynska-Read ◽

Dan Wang ◽

Song Liu ◽

James L. Mohler ◽

Donald L. Trump ◽

...

Keyword(s):

Prostate Cancer ◽

North Carolina ◽

Cancer Patients ◽

Racial Differences ◽

The North ◽

Genome Wide ◽

Cancer Project

Download Full-text

Equity in patient-provider communication regarding treatment-related symptoms and health-related quality of life (HRQOL) among breast cancer survivors.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.26_suppl.127 ◽

2016 ◽

Vol 34 (26_suppl) ◽

pp. 127-127

Author(s):

Cleo A. Samuel ◽

Jennifer Schaal ◽

Linda Robertson ◽

Eugenia Eng ◽

Jemeia G Kollie ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Racial Differences ◽

Symptom Management ◽

Breast Cancer Survivors ◽

Physical Symptoms ◽

Black And White ◽

Related Quality ◽

Health Related ◽

Patient Provider Communication

127 Background: Compared with white breast cancer patients, black patients more often report inadequate symptom control and decrements in health-related quality of life (HRQOL). Racial differences in patient-provider communication (PPC) are well-documented and linked to worse health outcomes for minorities; however, less is known about inequities in symptom and HRQOL discussions among cancer patients and providers. As part of an NCI-funded systems change intervention to improve racial equity in treatment completion among Black and White cancer patients, we assessed racial differences in PPC regarding treatment-related symptoms, HRQOL issues (e.g., physical, psychosocial, financial, and spiritual well-being), and symptom management among breast cancer survivors (BCS). Methods: We conducted 6 focus groups (FGs) and semi-structured interviews with 22 stage 1-3 BCS (3 black FGs; 3 white FGs) from 2 cancer centers. Guided by a community-based participatory research approach, our diverse community-academic-medical team facilitated FGs and conducted qualitative analyses. Results: Although both black and white BCS reported multiple treatment-related symptoms and changes in HRQOL, perspectives on PPC differed. Some black and white BCS described positive aspects of PPC, including providers’ thorough explanations of treatment side effects and responsiveness to symptom concerns. However, white BCS expressed greater satisfaction with PPC, while black BCS more often described concerns regarding providers’ verbal (e.g., nondisclosure, dismissiveness) and non-verbal communication (e.g., unapproachability, poor eye contact) skills in the context of symptom management. Most BCS, regardless of race, indicated that providers typically discussed physical symptoms/HRQOL issues, but often failed to mention non-physical side effects of treatment (e.g., social isolation, financial toxicity). Conclusions: Racial differences in PPC exist among BCS and may contribute to inequities in symptom management and HRQOL. Inadequate communication regarding non-physical symptoms likely represents a critical missed opportunity for improving the quality and equity of palliative care.

Download Full-text

Associations between patient–provider communication and socio-cultural factors in prostate cancer patients: A cross-sectional evaluation of racial differences

Patient Education and Counseling ◽

10.1016/j.pec.2014.08.019 ◽

2014 ◽

Vol 97 (3) ◽

pp. 339-346 ◽

Cited By ~ 23

Author(s):

Lixin Song ◽

Mark A. Weaver ◽

Ronald C. Chen ◽

Jeannette T. Bensen ◽

Elizabeth Fontham ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Racial Differences ◽

Cultural Factors ◽

Provider Communication ◽

Cross Sectional ◽

Patient Provider Communication

Download Full-text

Mitochondrial Cytochrome c Oxidase Subunit 1 Sequence Variation in Prostate Cancer

Scientifica ◽

10.6064/2012/701810 ◽

2012 ◽

Vol 2012 ◽

pp. 1-7 ◽

Cited By ~ 3

Author(s):

Takara A. Scott ◽

Rebecca S. Arnold ◽

John A. Petros

Keyword(s):

Prostate Cancer ◽

Cytochrome C ◽

Cancer Patients ◽

Cytochrome C Oxidase ◽

Racial Differences ◽

Reference Sequence ◽

Coi Gene ◽

Missense Mutations ◽

Mtdna Mutations ◽

Oxidase Subunit

Purpose. Mitochondrial DNA (mtDNA) mutations have been described in every adult neoplasm including prostate cancer. There are marked racial differences in mutations within the cytochrome c oxidase subunit 1 (COI) gene in individuals with prostate cancer (PCa). The purpose of this study was to identify the variation in COI gene sequence in African and Caucasian Americans with prostate cancer.Methods. We sequenced the COI gene from peripheral blood in 482 prostate cancer patients and 189 controls. All bases that differed from the revised Cambridge Reference Sequence (rCRS) were classified as either silent or missense and the compiled alterations were then compared between races and published reports.Results and Conclusions. We found inherited mtDNA COI missense variants in 8.8% of Caucasian prostate cancer patients (vs. 0.0% controls) and 72.8% of African-American prostate cancer patients (vs. 64.3% controls) A total of 144 COI variants were identified, of which 30 were missense mutations. Of 482 PCa patients, 116 (24.1%) had one or more missense mutations. Further evaluation of this gene and these mutations may allow for the identification of genetically at-risk populations. The high rate of COI mutations in African-Americans may account for some of the racial disparity observed in prostate cancer.

Download Full-text

Retzius-sparing robotic-assisted laparoscopic radical prostatectomy: Racial considerations for 250 consecutive cases.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.15_suppl.e17546 ◽

2020 ◽

Vol 38 (15_suppl) ◽

pp. e17546-e17546

Author(s):

Rabii Madi ◽

Rashid K. Sayyid ◽

Dalton Sherwood ◽

Zachary William Abraham Klaassen

Keyword(s):

Prostate Cancer ◽

Radical Prostatectomy ◽

Cancer Patients ◽

Racial Differences ◽

Case Series ◽

Primary Objective ◽

Laparoscopic Radical Prostatectomy ◽

Oncologic Outcomes ◽

Robotic Assisted ◽

One Year

e17546 Background: To report the functional and oncologic outcomes of a cohort of 250 consecutive prostate cancer patients undergoing a Retzius-sparing approach and to assess for racial differences in continence outcomes. Methods: This was a prospective, single-center, case series of 250 consecutive prostate cancer patients who underwent a Retzius-sparing robotic assisted laparoscopic radical prostatectomy by a single surgeon between May 2015 and April 2019.Our primary objective was to describe post-operative continence outcomes of patients undergoing this technique. Results: Median follow up was 24.0 months [Interquartile range (IQR) 18.0-30.0 months]. Median age and body mass index were 62.0 years (IQR 57.0-67.0) and 29.0 kg/m 2 (IQR 26.0-33.0), respectively. Median PSA was 8.22 ng/ml (IQR 5.74-13.31). 84.8% of patients were intermediate or high-risk pre-operatively. 96.0% had Gleason Score 7 or worse disease on final pathologic analysis. Positive margin incidence was 18.1% and 44.4% in patients with pT2 and pT3 disease, respectively. Immediate continence (i.e. continence achieved within one moth post-operatively) was achieved in 45.0% of patients. One-year continence rate was 92.0%. Caucasian patients experienced earlier return of continence (77% versus 65% at 3 months) compared to African American patients. IPSS scores gradually improved from 8.0 pre-operatively to 4.0 one year later. Median PSA level was 0.01 ng/ml (IQR 0.01-9.01) post-operatively. Conclusions: Retzius-sparing robotic assisted laparoscopic radical prostatectomy is an oncologically safe surgical technique with excellent short and long-term continence outcomes.

Download Full-text